Skip to main content

Advertisement

SpringerLink
Log in

Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Breast cancer is the leading type of cancer in Iranian women and affects them at least one decade younger than their counterparts in developed countries. Breast tumor progression and metastasis is accompanied by a decrease in the membranous expression of Syndecan-1 and an increase in its shedding. We measured the level of soluble Syndecan-1 in the sera of Iranian patients with breast cancer.

Methods

The study population included 61 chemotherapy-naïve breast cancer patients and 30 age/sex-matched healthy individuals. Blood was collected by venipuncture method and serum was separated, aliquoted and kept at −40 °C until used. A commercial ELISA was used to detect Syndecan-1 levels in the sera.

Results

Soluble Syndecan-1 levels were increased in the sera of patients with breast cancer compared to healthy controls (87.89 ± 89.29 vs. 47.57 ± 46.46 ng/ml, p = 0.005). There was a positive correlation between soluble Syndecan-1 levels and tumor size (p = 0.017). The serum level of Syndecan-1 in patients without calcification showed a trend of increase compared to that of patients with calcification (108.80 ± 101.76 vs. 59.82 ± 57.13 ng/ml).

Conclusion

The positive correlation between soluble Syndecan-1 levels and tumor size in the present study highlights the importance of different varieties (cell-bound and soluble) of this molecule in the breast tumor progression and their significance as tumor biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma–rare types: review of the literature. Ann Oncol. 2009;20(11):1763–70.

    Article  CAS  PubMed  Google Scholar 

  2. WHO. Breast cancer: prevention and control. In: Organization WH, editor.

  3. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56.

    Article  PubMed  Google Scholar 

  4. Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519–27.

    Article  PubMed  Google Scholar 

  5. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24–7.

    PubMed  Google Scholar 

  6. Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in Iran, a national study. Iran Red Crescent Med J. 2012;14(12):798–804.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rahimzadeh M, Pourhoseingholi MA, Kavehie B. Survival rates for breast cancer in iranian patients: a meta-analysis. Asian Pac J Cancer Prev. 2016;17(4):2223–7.

    Article  PubMed  Google Scholar 

  8. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11(6):541–52.

    Article  CAS  PubMed  Google Scholar 

  9. Purushothaman A, Sanderson RD. Atlas of genetics and cytogenetics in oncology and haematology. 2008 [cited 2016 September]. http://atlasgeneticsoncology.org/Genes/GC_SDC1.html.

  10. Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells. 2007;24(2):153–66.

    CAS  PubMed  Google Scholar 

  11. Gotte M, Echtermeyer F. Syndecan-1 as a regulator of chemokine function. Sci World J. 2003;3:1327–31.

    Article  Google Scholar 

  12. Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, Rops AL, et al. Role of the heparan sulfate proteoglycan Syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol (Baltimore, Md: 1950). 2009;182(8):4985–93.

  13. Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood. 2009;114(14):3033–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Fears CY, Woods A. The role of syndecans in disease and wound healing. Matrix Biol. 2006;25(7):443–56.

    Article  CAS  PubMed  Google Scholar 

  15. Akl MR, Nagpal P, Ayoub NM, Prabhu SA, Gliksman M, Tai B, et al. Molecular and clinical profiles of Syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget. 2015;6(30):28693–715.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Shegefti MS, Malekzadeh M, Malek-Hosseini Z, Khademi B, Ghaderi A, Doroudchi M. Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma. Laryngoscope. 2016;126(5):E191–5.

    Article  CAS  PubMed  Google Scholar 

  17. Rintala M, Inki P, Klemi P, Jalkanen M, Grenman S. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol. 1999;75(3):372–8.

    Article  CAS  PubMed  Google Scholar 

  18. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Can Res. 2001;61(14):5562–9.

    CAS  Google Scholar 

  19. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88(1):12–20.

    Article  CAS  PubMed  Google Scholar 

  20. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, et al. Differential roles for membrane-bound and soluble Syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30(3):397–407.

    Article  CAS  PubMed  Google Scholar 

  21. Szatmari T, Otvos R, Hjerpe A, Dolora K. Syndecan-1 in cancer: implications for cell signaling, differentiation, and prognostication. Dis Mark. 2015;2015:796052. doi:10.1155/2015/796052.

    Google Scholar 

  22. Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31(1):3–16.

    Article  CAS  PubMed  Google Scholar 

  23. Kim SY, Choi EJ, Yun JA, Jung ES, Oh ST, Kim JG, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci. 2015;12(2):92–9.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell. 1995;6(5):559–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, et al. Shift of Syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer. 2004;40(9):1373–82.

    Article  CAS  PubMed  Google Scholar 

  26. Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of Syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272(23):14713–20.

    Article  CAS  PubMed  Google Scholar 

  27. Ishikawa T, Kramer RH. Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res. 2010;316(6):951–65.

    Article  CAS  PubMed  Google Scholar 

  28. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, et al. Cleavage of Syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem. 2003;278(42):40764–70.

    Article  CAS  PubMed  Google Scholar 

  29. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, et al. High Syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98(3):474–83.

    Article  PubMed  Google Scholar 

  30. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of Syndecan-1 expression in breast cancer. Oncology. 2004;67(1):11–8.

    Article  CAS  PubMed  Google Scholar 

  31. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, et al. Prognostic impact of Syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008;98(12):1993–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sanaee MN, Malekzadeh M, Khezri A, Ghaderi A, Doroudchi M. Soluble CD138/Syndecan-1 increases in the sera of patients with moderately differentiated bladder cancer. Urol Int. 2015;94(4):472–8.

    Article  CAS  PubMed  Google Scholar 

  33. The Human Protein Atlas [cited 2016 September]. http://www.proteinatlas.org/ENSG00000138798-EGF/tissue.

  34. Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (Georgetown, Tex). 2012;11(15):2922–30.

  35. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Stiehl DP, Bordoli MR, Abreu-Rodriguez I, Wollenick K, Schraml P, Gradin K, et al. Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene. 2012;31(18):2283–97.

    Article  CAS  PubMed  Google Scholar 

  37. Ansell A, Jedlinski A, Johansson AC, Roberg K. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. J Oral Pathol Med. 2016;45(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  38. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009;122(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  39. Ling H, Liu ZB, Xu LH, Xu XL, Liu GY, Shao ZM. Malignant calcification is an important unfavorable prognostic factor in primary invasive breast cancer. Asia Pac J Clin Oncol. 2013;9(2):139–45.

    Article  PubMed  Google Scholar 

  40. Nyante SJ, Lee SS, Benefield TS, Hoots TN, Henderson LM. The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort. Cancer. 2016;. doi:10.1002/cncr.30281.

    PubMed  Google Scholar 

Download references

Acknowledgements

This work was performed as part of Sina Jelodar dissertation as a requirement for graduation as a general practitioner from Shiraz Medical School (Shiraz, Iran). This project was financially supported by a Grant (90-01-2779) from Shiraz University of Medical Sciences and was performed and supported by Shiraz Institute for Cancer Research, Shiraz, Iran (Grant ICR-100-502).

Author information

Authors and Affiliations

  1. Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, P.O. Box: 71345-3119, Shiraz, 71348-45794, Iran

    Zahra Malek-Hosseini, Sina Jelodar, Abbas Ghaderi & Mehrnoosh Doroudchi

  2. Breast Disease Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Abdolrasoul Talei

  3. Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran

    Abbas Ghaderi & Mehrnoosh Doroudchi

Authors
  1. Zahra Malek-Hosseini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sina Jelodar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdolrasoul Talei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abbas Ghaderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehrnoosh Doroudchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehrnoosh Doroudchi.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 18 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malek-Hosseini, Z., Jelodar, S., Talei, A. et al. Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size. Breast Cancer 24, 742–747 (2017). https://doi.org/10.1007/s12282-017-0773-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-017-0773-0

Keywords

Search

Navigation